Astrazeneca (AZN) Current Taxes (2009 - 2026)

Astrazeneca has reported Current Taxes for 18 years, with the latest figure at -$649.0 million in Q2 2026.

• On a quarterly basis, Current Taxes fell 33.81% year-over-year to -$649.0 million in Q2 2026; TTM through Jun 2026 was -$649.0 million, a 33.81% decrease from a year earlier, with the FY2025 full-year figure at -$700.0 million, down 194.12% from the prior year.
• Current Taxes was -$649.0 million for Q2 2026 at Astrazeneca, down from -$611.0 million in the prior quarter.
• The five-year high for Current Taxes was -$174.0 million in Q3 2024, with the low at -$1.6 billion in Q1 2024.
• Average Current Taxes over 5 years is -$892.0 million, with a median of -$938.5 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Current Taxes soared 85.04% in 2024, then slumped 207.47% in 2025.
• Over 5 years, Current Taxes stood at -$896.0 million in 2022, then plunged by 76.79% to -$1.6 billion in 2023, then surged by 84.97% to -$238.0 million in 2024, then tumbled by 194.12% to -$700.0 million in 2025, then increased by 7.29% to -$649.0 million in 2026.
• The last three Current Taxes figures came in at -$649.0 million (Q2 2026), -$611.0 million (Q1 2026), and -$700.0 million (Q4 2025), per Business Quant data.